Apollo Management Holdings L.P. Has $4.27 Million Stock Position in MannKind Co. (NASDAQ:MNKD)

Apollo Management Holdings L.P. decreased its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 31.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 664,113 shares of the biopharmaceutical company's stock after selling 300,000 shares during the period. MannKind makes up 0.1% of Apollo Management Holdings L.P.'s portfolio, making the stock its 22nd largest holding. Apollo Management Holdings L.P. owned approximately 0.24% of MannKind worth $4,270,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Northern Trust Corp grew its position in MannKind by 8.1% in the 4th quarter. Northern Trust Corp now owns 2,777,784 shares of the biopharmaceutical company's stock worth $17,861,000 after purchasing an additional 207,792 shares during the last quarter. Aquatic Capital Management LLC grew its position in MannKind by 11.9% during the fourth quarter. Aquatic Capital Management LLC now owns 181,074 shares of the biopharmaceutical company's stock worth $1,164,000 after buying an additional 19,274 shares in the last quarter. Oxford Asset Management LLP bought a new position in MannKind during the fourth quarter valued at about $95,000. Kovitz Investment Group Partners LLC acquired a new position in MannKind in the 4th quarter valued at approximately $65,000. Finally, Oberweis Asset Management Inc. lifted its position in shares of MannKind by 21.2% in the 4th quarter. Oberweis Asset Management Inc. now owns 968,400 shares of the biopharmaceutical company's stock worth $6,227,000 after acquiring an additional 169,600 shares during the period. Institutional investors own 49.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on MNKD shares. Mizuho assumed coverage on MannKind in a research report on Thursday, April 10th. They set an "outperform" rating and a $12.00 price objective on the stock. StockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. Finally, Wedbush reaffirmed an "outperform" rating and set a $11.00 price objective on shares of MannKind in a report on Thursday, February 27th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $9.56.

MannKind Stock Performance

Shares of NASDAQ:MNKD traded up $0.05 on Friday, hitting $5.00. The stock had a trading volume of 1,639,769 shares, compared to its average volume of 2,386,936. The firm's 50 day moving average price is $4.94 and its 200-day moving average price is $5.89. MannKind Co. has a twelve month low of $4.17 and a twelve month high of $7.63. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of 71.43 and a beta of 1.14.

MannKind (NASDAQ:MNKD - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported $0.03 EPS for the quarter, meeting analysts' consensus estimates of $0.03. The firm had revenue of $76.78 million for the quarter, compared to analyst estimates of $74.99 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. As a group, sell-side analysts predict that MannKind Co. will post 0.1 EPS for the current year.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.